Makhlouf Hala R, Ishak Kamal G, Shekar Raj, Sesterhenn Isabell A, Young Denise Y, Fanburg-Smith Julie C
Department of Hepatic and Gastrointestinal Pathology, Armed Forces Institute of Pathology, Washington, DC 20306-6000, USA.
Arch Pathol Lab Med. 2002 Jan;126(1):49-55. doi: 10.5858/2002-126-0049-MMIAOT.
Melanoma markers, especially the new microphthalmia transcription factor (mitf), have not been previously compared in hepatic and renal angiomyolipomas.
To evaluate expression of the novel melanocytic markers mitf and tyrosinase in angiomyolipomas, and to compare these markers with the established markers HMB-45 and melan-A in both hepatic and renal tumors.
Clinical, histopathologic, and immunohistochemical features of 15 hepatic angiomyolipomas were compared with those of 10 renal angiomyolipomas.
No significant differences between patients with hepatic angiomyolipomas and renal angiomyolipomas were found with respect to age, gender, race, and tumor size. Hepatic angiomyolipomas exhibited a predominance of the epithelioid smooth muscle cell component, in contrast to their renal counterparts, which were predominantly spindled. The smooth muscle cells expressed HMB-45 in 100% of cases in both groups, melan-A in 14 of 15 hepatic angiomyolipomas and 8 of 9 renal angiomyolipomas, mitf in 5 of 12 hepatic angiomyolipomas versus 6 of 10 renal angiomyolipomas, and tyrosinase in 3 of 12 and 2 of 10 hepatic angiomyolipomas and renal angiomyolipomas, respectively. The extent and intensity of immunostaining with HMB-45 and melan-A were dependent on whether spindled or epithelioid cells predominated; the epithelioid cells showed stronger and more widespread reactivity than the spindled cells.
We believe that the best immunohistochemical marker for confirming the diagnosis of angiomyolipoma is HMB-45, followed by melan-A. Routine use of mitf and/or tyrosinase is not indicated.
黑色素瘤标志物,尤其是新型小眼畸形转录因子(mitf),此前尚未在肝脏和肾脏血管平滑肌脂肪瘤中进行比较。
评估新型黑素细胞标志物mitf和酪氨酸酶在血管平滑肌脂肪瘤中的表达,并将这些标志物与肝脏和肾脏肿瘤中已确立的标志物HMB-45和黑素A进行比较。
比较15例肝脏血管平滑肌脂肪瘤与10例肾脏血管平滑肌脂肪瘤的临床、组织病理学和免疫组化特征。
肝脏血管平滑肌脂肪瘤患者与肾脏血管平滑肌脂肪瘤患者在年龄、性别、种族和肿瘤大小方面未发现显著差异。与肾脏血管平滑肌脂肪瘤主要为梭形细胞不同,肝脏血管平滑肌脂肪瘤以上皮样平滑肌细胞成分为主。两组中100%的病例平滑肌细胞表达HMB-45,15例肝脏血管平滑肌脂肪瘤中的14例和9例肾脏血管平滑肌脂肪瘤中的8例表达黑素A,12例肝脏血管平滑肌脂肪瘤中的5例与10例肾脏血管平滑肌脂肪瘤中的6例表达mitf,12例肝脏血管平滑肌脂肪瘤中的3例和10例肾脏血管平滑肌脂肪瘤中的2例分别表达酪氨酸酶。HMB-45和黑素A免疫染色的范围和强度取决于梭形细胞还是上皮样细胞占主导;上皮样细胞比梭形细胞表现出更强且更广泛出现的反应性。
我们认为,用于确诊血管平滑肌脂肪瘤的最佳免疫组化标志物是HMB-45,其次是黑素A。不建议常规使用mitf和/或酪氨酸酶。